绿色巴西提取物能否改善症状慢性冠状动脉疾病的功能能力?-试点随机试验
Clara Salles Figueiredo1,2, Luiz Carlos Santana Passos1,2, Caio Rebouças Fonseca Cafezeiro2
1Programa de Pós-Graduação em Medicina e Saúde (Graduate Program in Medicine and Health), Faculdade de Medicina da Bahia, Universidade Federal da Bahia, Salvador 40110-060, BA, Brazil.
Pharmaceuticals (Basel, Switzerland)
|June 27, 2025
概括
绿色巴西提取物 (EPP-AF®) 补充剂没有改善冠状动脉病 (CHD) 患者的功能能力或减少炎症. 这项试点研究发现,与安慰剂相比,在六周内没有显著的益处.
科学领域:
- 心血管医学 心血管医学
- 营养保健品 营养保健品
- 炎症研究 炎症研究
背景情况:
- 炎症是冠心病 (CHD) 进展的关键驱动因素.
- 绿色巴西提取物 (EPP-AF®) 具有抗炎性质.
- 对于心血管事件,EPP-AF®可能会提供超越标准医疗治疗的额外好处.
研究的目的:
- 评估EPP-AF®补充剂在稳定心脏病患者改善功能能力方面的有效性.
- 评估EPP-AF®对炎症标志物和心痛症状的影响.
主要方法:
- 一项随机,双盲,安慰剂控制的试点研究,涉及59名稳定的心血管疾病患者.
- 参与者每天两次接受200毫克EPP-AF®或安慰剂,持续6周.
- 主要结局:跑步机运动持续时间的变化;次要结局:METs,hs-CRP,SAQ和CCS类.
主要成果:
- 在EPP-AF®和安慰剂组之间,跑步机运动持续时间没有显著差异 (p = 0.83).
- 补充EPP-AF®并没有导致功能能力 (METs),hs-CRP水平或心痛得分 (SAQ,CCS) 的改善.
- 在这两组中都没有报告任何重大心血管不良事件.
结论:
- 六周EPP-AF®补充剂没有改善稳定心脏病患者的功能能力.
- 与安慰剂相比,EPP-AF®在减少炎症标志物或胸痛症状方面没有显示出益处.
- 需要进一步的研究来探索在心血管健康中的潜在治疗作用.
相关概念视频
01:26Coronary Artery Disease IV: Preventive Measures
39
Effective preventive measures for coronary artery disease (CAD) focus on controlling modifiable risk factors, including cholesterol abnormalities and lifestyle changes.Cholesterol ManagementFirst, the Mediterranean diet and the American Heart Association advocate for maintaining low-density lipoprotein (LDL) cholesterol levels below 100 mg/dL, with a more stringent recommendation of below 70 mg/dL for individuals at high risk. LDL cholesterol, often termed "bad cholesterol," can lead to the...
39
01:27Chronic Obstructive Pulmonary Disease-IV: Assessement and Diagnostic Studies
2.6K
Assessing and diagnosing Chronic Obstructive Pulmonary Disease (COPD) involves a detailed approach that includes a comprehensive review of medical history, physical examination, and a variety of diagnostic tests. This thorough evaluation is essential to ensure an accurate diagnosis and guide effective management strategies.
Medical History
Medical History
2.6K
01:30Coronary Artery Disease III: Clinical Manifestations
38
Coronary Artery Disease (CAD) is a primary health risk worldwide, leading to significant morbidity and mortality. The condition arises from the buildup of atherosclerotic plaques within the coronary arteries, resulting in diminished blood supply to the heart muscle.The clinical manifestations of CAD vary widely, from asymptomatic stages to severe, life-threatening conditions. Understanding these manifestations is crucial for early diagnosis and effective management.Angina Pectoris: The Warning...
38
01:25Pulmonary Function Tests
437
Pulmonary Function Tests (PFTs)
Pulmonary Function Tests are crucial diagnostic tools for assessing respiratory function, particularly in patients with chronic respiratory disorders. They comprehensively evaluate lung volumes, ventilatory function, breathing mechanics, diffusion, and gas exchange. These tests help diagnose pulmonary diseases and play a significant role in monitoring disease progression, evaluating disability, and assessing response to therapy.
PFTs involve using a spirometer, a...
Pulmonary Function Tests are crucial diagnostic tools for assessing respiratory function, particularly in patients with chronic respiratory disorders. They comprehensively evaluate lung volumes, ventilatory function, breathing mechanics, diffusion, and gas exchange. These tests help diagnose pulmonary diseases and play a significant role in monitoring disease progression, evaluating disability, and assessing response to therapy.
PFTs involve using a spirometer, a...
437
01:30Acute Coronary Syndrome III: Diagnostic Studies
26
Diagnosing acute coronary syndrome or ACS begins with a thorough patient history. Notable symptoms include central, crushing chest pain radiating to the left arm, neck, jaw, or back, along with shortness of breath, sweating (diaphoresis), nausea, vomiting, dizziness, and palpitations.It is crucial to note any history of cardiac illnesses and assess risk factors, including age, gender, smoking, hypertension, diabetes, hyperlipidemia, and a sedentary lifestyle.During physical examination, vital...
26
01:22Chronic Obstructive Pulmonary Disease
1.4K
COPD is defined as a heterogeneous lung condition marked by persistent respiratory symptoms such as dyspnea, cough, and sputum production, caused by abnormalities in the airways that cause airflow obstruction.
Smoking is a primary risk factor for COPD, with over 80% of patients having a history of it. Patients typically experience progressive dyspnea or labored breathing, frequent coughing, and recurrent pulmonary infections. Many eventually succumb to respiratory failure, characterized by...
Smoking is a primary risk factor for COPD, with over 80% of patients having a history of it. Patients typically experience progressive dyspnea or labored breathing, frequent coughing, and recurrent pulmonary infections. Many eventually succumb to respiratory failure, characterized by...
1.4K